Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Gynecol Oncol. 2023 Nov 17;179:115–122. doi: 10.1016/j.ygyno.2023.10.017

Figure 1:

Figure 1:

Final overall survival results from the Gynecologic Oncology Group (GOG) protocol 240. Kaplan-Meier curves depicting the intent-to-treat final protocol-specified overall survival comparing cisplatin plus paclitaxel with and without bevacizumab.

OS: overall survival; HR: hazard ratio; CI: confidence interval; Cis: cisplatin; Pac: paclitaxel; Bev: bevacizumab

Reprinted from The Lancet, Volume 390, Tewari KS, Sill MW, Penson RT, et al., Final overall survival of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study, Pages 1654–1663, Copyright (2017), with permission from Elsevier. This figure is made available under the CC BY-NC-ND 4.0 license.